Diabetic macular edema and diabetic macular ischemia Diabetic macular edema and diabetic macular ischemia Diabetic macular edema and diabetic macular ischemia are complications of diabetic retinopathy.
The big, the bold, and the few The big, the bold, and the few In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
Difficulties Chewing and Swallowing Difficulties Chewing and Swallowing Discover tips on how to overcome difficulties in chewing and swallowing food from Taking Cancer On Through Flavour
Boehringer Ingelheim and Fraunhofer partnership Boehringer Ingelheim and Fraunhofer partnership Boehringer Ingelheim and Fraunhofer IME launch collaboration which aims to develop sustainable animal health products
Boehringer Ingelheim and GST prepared bring innovation to equine market Boehringer Ingelheim and GST prepared bring innovation to equine market Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market
Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry Boehringer Ingelheim demonstrates its commitment to farm animal well-being by organising its 11th Expert Forum on Farm Animal Well-Being
European Metacam® indication expanded to guinea pigs European Metacam® indication expanded to guinea pigs Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.
New indications NexGard, NexGard SPECTRA and Broadline New indications NexGard, NexGard SPECTRA and Broadline New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
Fight against COVID-19 pandemic Fight against COVID-19 pandemic Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Veterinarians: caught between excellence and exhaustion Veterinarians: caught between excellence and exhaustion Many children dream of becoming a veterinarian. What happens when that dream comes true?
Expand your professional experiences Expand your professional experiences Identify the skills you have, and those you might need, to get your dream job. This video will show you how.
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
How fast can a cheetah run wild and free? How fast can a cheetah run wild and free? Cheetahs’ top speed can reach up to 120km/h. But habitat loss, illegal wildlife trade and hunting made these impressive animals critically endangered.
Boehringer expands cancer research at Vienna site Boehringer expands cancer research at Vienna site Boehringer Ingelheim expands cancer research at its Vienna site
Heart murmur in dogs: symptoms and how to treat it Heart murmur in dogs: symptoms and how to treat it Monitoring your dog’s heart can save its life
All hands-on deck to fight the ‘zombie’ rabies virus All hands-on deck to fight the ‘zombie’ rabies virus We’re teaming up with communities and governments across Southeast Asia to fight rabies through vaccinations, education programs, and partnerships.
Uniting to stop rabies: a global and local endeavor Uniting to stop rabies: a global and local endeavor By collaborating together, we can stop rabies. Read how we are breaking down barriers through the power of partnerships to fight this deadly disease
Breakthrough introduction innovation pet parasiticides Breakthrough introduction innovation pet parasiticides In 2014, Boehringer introduced a new product, which became the first in a new class of isoxazoline products for flea and tick protection in dogs.
Women in STEM 2022 Women in STEM 2022 Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
GioTag Final Data GioTag Final Data Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
EMPRISE-interim-analysis EMPRISE-interim-analysis Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists